Nexalin Cleared the First of Two Nasdaq Panel Conditions on Sept. 30; the Second Requires $2.5 Million of Stockholders' Equity by Jan. 4, 2027, Against $1.52 Million Reported at June 30
Nexalin Technology, Inc. (Nasdaq: NXL) received formal notice from Nasdaq on Sept. 30 that it has regained compliance with the $1.00 minimum bid price rule, the Houston company said in a Form 8-K filed Oct. 1. That satisfies the first of two conditions a Nasdaq Hearings Panel attached to its continued listing. The second, stated in a Sept. 28 8-K, is that "on or before January 4, 2027, the Company shall demonstrate compliance with the Stockholders' Equity Requirement" of $2,500,000 under Listing Rule 5550(b)(1).
The Panel's decision, received Sept. 25 and disclosed in the Sept. 28 filing, granted Nexalin's request for continued listing "subject to the conditions that (1) on or before September 28, 2026, the Company shall demonstrate compliance with the Minimum Bid Price Requirement and (2) on or before January 4, 2027, the Company shall demonstrate compliance with the Stockholders' Equity Requirement." The same filing says the Panel "will also require the Company to demonstrate a closing bid price of $1.00 or greater per share for a minimum of 20 consecutive trading sessions," a longer test than the ten consecutive business days specified in the staff's January compliance letter, as the company's Oct. 8 S-1/A recounts it; the 8-K says the additional requirement was imposed under Rule 5815(c)(4).
The Oct. 1 filing is explicit about what failure means. "If the Company fails to demonstrate compliance with the Stockholders' Equity Requirement on or before January 4, 2027, or otherwise fails to comply with the terms of the Notice, the Company's common stock will be subject to delisting from Nasdaq," it says, adding that "There can be no assurance" the company will meet the deadline.
The gap to close is quantified in Nasdaq's own correspondence. An Aug. 17 8-K disclosed a letter from the Listing Qualifications staff dated Aug. 14 stating that, "based on the stockholders' equity of $1,519,423 reported in the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2026, the Company no longer satisfies the minimum stockholders' equity requirement of $2,500,000." The letter also noted that Nexalin did not meet either alternative standard under Rule 5550(b); Nasdaq's rulebook sets those at "Market Value of Listed Securities of at least $35 million" or "Net income from continuing operations of $500,000 in the most recently completed fiscal year or in two of the three most recently completed fiscal years."
The bid-price side of the case had already escalated to a delisting determination. Nexalin was first notified on Jan. 21, 2026 that its stock had closed below $1.00 for 30 consecutive business days and was given until July 20 to recover, according to a July 27 8-K. On July 24 it received a Staff Determination letter saying it "has not regained compliance" and "is not eligible for a second 180-day compliance period because the Company does not comply with the $5,000,000 minimum stockholders' equity initial listing requirement for The Nasdaq Capital Market." Suspension was scheduled for Aug. 4 unless the company appealed; it did, and the hearing took place Sept. 1, the Sept. 28 filing says.
The cure for the bid price was a 1-for-30 reverse split. The company's Form S-1/A filed Oct. 8 says it filed a certificate of amendment in Delaware on Aug. 26 and that, effective Aug. 28 at 5:00 p.m. Eastern, every 30 shares were combined into one. The same filing states that it had 1,048,527 shares of common stock outstanding as of Oct. 7, 2026, against 22,003,706 shares issued and outstanding at June 30 on a pre-split basis, per the 10-Q. The S-1/A gives the last reported Nasdaq sale price on Oct. 7 as $4.32 per share; we have not located a dated closing price for Oct. 9 in the company's filings and do not state one.
Nexalin makes the Nexalin Sync, which it describes in filings as a non-invasive neurostimulation device. Its 10-Q for the quarter ended June 30, filed Aug. 12, reports no international revenue in the quarter or the six months and says its "limited revenue in these periods was derived from legacy Gen-1 licensing fees and electrode sales in the United States." As of June 30 the company had an accumulated deficit of approximately $97,203,000, a six-month loss from operations of approximately $4,367,000, negative operating cash flow of approximately $3,515,000 and cash and cash equivalents of approximately $1,005,000. Total stockholders' equity was $1,519,423, down from $3,747,986 at Dec. 31, 2025, the balance sheet shows.
The 10-Q's liquidity note says management "does not currently have sufficient cash and cash equivalents to fund its anticipated operating requirements for at least twelve months" and that its plans "do not alleviate the substantial doubt" about the company's ability to continue as a going concern.
The equity requirement is being attacked with several instruments at once. A prospectus supplement filed Aug. 20 covered the sale of 2,419,354 pre-split shares at $0.31 to a single accredited investor for gross proceeds of approximately $750,000, with concurrent private-placement warrants for 1,209,677 shares at $0.50, exercisable immediately and expiring one year from issuance. The same day, Aug. 19, Nexalin signed an "Any Market Purchase Agreement" with Alumni Capital, LP, under which it may direct the investor to buy up to $15,000,000 of common stock through Dec. 31, 2027 at, at the company's election, 92% of the lowest daily volume-weighted average price over the three business days before closing or a formula tied to the prior day's lowest traded price, according to the S-1/A. The S-1/A registers the resale of up to 5,752,823 shares, including 5,600,000 shares that may be sold to Alumni and 112,500 commitment-fee shares.
At-the-market sales have moved faster. The S-1/A says that during the week ended Oct. 2 the company sold 219,593 shares under its ATM program for gross proceeds of approximately $1.9 million and net proceeds of approximately $1.8 million after commissions. Of that, approximately $378,000, or 20% of gross proceeds, went to a mandatory prepayment of a promissory note issued Aug. 21, reducing the note's balance to approximately $792,000, and approximately $189,000, equal to 10% of gross proceeds, was paid to Alumni Capital under a side letter for its consent to the ATM sales, the filing says.
Whether those sales lift equity above $2.5 million is not something the filings answer. Stockholders' equity is a balance-sheet figure measured at a period end, and the next scheduled test is the Sept. 30 quarter, to be reported in a 10-Q due in November. The $1,519,423 figure dates from June 30, before the $750,000 August sale, the ATM proceeds and the third quarter's operating loss, none of which has been netted in any published balance sheet. Nexalin's own disclosure says only that it "intends to take all steps necessary to satisfy the Stockholders' Equity Requirement on or before January 4, 2027."
The company also announced a commercial agreement in the same window. An Oct. 1 8-K described a ten-year exclusive distribution agreement, effective Sept. 22, with the founders of INOVANEXA Medical Technologies S.A., a Brazilian corporation "in formation," covering Brazil, Argentina, Chile, Uruguay, Paraguay, Ecuador and Venezuela. It calls for an initial binding order of five Nexalin Sync devices for a clinical pilot "targeted to launch within 90 days" and a further five within twelve months, with an initial 100-device program at tiered pricing. The 8-K says the distributor "is not otherwise obligated to purchase additional Products" beyond those orders, subject to revenue thresholds that preserve exclusivity.
What is next: the September-quarter 10-Q will give the first post-split, post-raise equity figure; the Panel's Jan. 4, 2027 deadline then leaves time for a year-end balance sheet or an interim showing. Unknown from the filings are how many ATM shares have been sold since Oct. 2, whether any Alumni purchases have begun, and whether the Aug. 28 split's 20-session bid-price test has been fully run; the Oct. 1 8-K says Nasdaq confirmed compliance but does not describe the sessions counted.
Sources & further reading
- Nexalin Technology, Inc., Form 8-K (Item 8.01), filed Oct. 1, 2026
- Nexalin Technology, Inc., Form 8-K (Item 3.01, Hearings Panel decision), filed Sept. 28, 2026
- Nexalin Technology, Inc., Form 8-K (Item 3.01, stockholders' equity letter), filed Aug. 17, 2026
- Nexalin Technology, Inc., Form 8-K (Item 3.01, Staff Determination), filed July 27, 2026
- Nexalin Technology, Inc., Form 10-Q for the quarter ended June 30, 2026, filed Aug. 12, 2026
- Nexalin Technology, Inc., Form S-1/A (resale registration, Alumni Capital AMPA), filed Oct. 8, 2026
- Nexalin Technology, Inc., Prospectus Supplement (424B5), filed Aug. 20, 2026
- Nasdaq Listing Center, Rule 5550(b) Continued Listing Standards for Primary Equity Securities (Nasdaq 5500 Series)
- Nexalin Technology, Inc., Form 8-K (Item 1.01, INOVANEXA distribution agreement), filed Oct. 1, 2026
